1Lusuardi M,Cape 1 li A,Carli S,etal.Role of surfactant in chronic obst ructive pulmonary disease:therapeuticimplications.Respiration,1992,59(Suppl 1): 28-32.
2Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol inanti-oxedant therapy.Respir Med,1998,92(4):609-623.
3Houtmeyers E.Effects of drugs on mucus clearance.Eur Respir J,1999,1 4(2):452-467.
4Zasshi NY.Effects of ambroxol HC1 on the guinea pig tracheal mucous secretion andthe rat pulmonary surfactant secretion.Uchida-M,1992,100(4):293-30 0.
5Derelle J,Bertolo HE,Marchal F,et al.Respiratory evolution of patien t withmucoviscidosis treated with mucolytic agents plus dornase alfa.Arch-Pediatr,1998,5(4):371-377.
6Nowak D,Antczak A,Krol M,et al.Antioxidant properties of ambroxol.Fr ee Radic BiolMed,1994,16(4):517-522.
8Dorow P,Weiss T.Modification of mucociliary clearance by a combinati on oftheophylline with ambroxol and of ambroxol in monotherapy.Arzneimittelforschung,1988,38(6):828-830.
10Michnar M,Milanowski J.Clinical evaluation of efficacy and tolerance oforaltreatment with ambroxol in patients with chronic bronchitis.Pneumonol-Alergol-Pol,1996,64(Suppl 1):90-96.
